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Abstract Malignant gliomas are currently diagnosed based
on morphological criteria and graded according to the World
Health Organization classification of primary brain tumors.
This algorithm of diagnosis and classification provides clini-
cians with an estimated prognosis of the natural course of
the disease. It does not reflect the expected response to
specific treatments beyond surgery (eg, radiotherapy or
alkylating chemotherapy). Clinical experience has revealed
that gliomas sharing similar histomorphological criteria
might indeed have different clinical courses and exhibit
highly heterogenous responses to treatments. This was very
impressively demonstrated first for oligodendrogliomas.
The presence or lack of combined deletions of the chromo-
somal segments 1p/19q was associated with different benefit
from radiotherapy and chemotherapy. We review current
molecular markers for malignant gliomas and discuss their
current and future impact on clinical neuro-oncology.
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Introduction
Malignant gliomas are a heterogeneous group of primary brain
tumors. The entities are distinguished based on morphological
criteria by histological analysis and presumed cell of origin.
The World Health Organization (WHO) classification is a
grading system integrating four ascending grades of malignan-
cy. It is based on histomorphological criteria [1] but has been
shaped by decades of clinical observation. The WHO classifi-
cation reflects the anticipated malignancy of the tumor and
serves as a criterion to estimate the prognosis of patients.
However, clinical experiences derived from prospective ran-
domized clinical trials indicate that histomorphological criteria
alone might not be sufficient to predict clinical outcome.
Gliomas even with identical histopathological features differ
considerably regarding clinical course or response to therapy.
Investigation of molecular genetics of the tumor may help to
overcome some of these limitations. Moreover, the analysis of
blood and urine for chemokines or enzymes as well as the
monitoring of circulating cellular subtypes in the peripheral
blood have emerged especially during the increasing repertoire
of targeted therapies, notably antiangiogenic therapies [2].
Clinicians expect these molecular aberrations or changing
expression levels in tumor tissue, blood, or urine ideally to
serve as diagnostic, prognostic, predictive, or surrogate bio-
markers. Molecular tumor characterization should also refine
the histopathologicalWHO classification and hopefully extend
it to allow predictions for specific therapeutic strategies. Bio-
markers may help for easy and reliable identification of res-
ponders to a specific treatment, and allow identification of
escape or resistance mechanisms during ongoing therapy. Sev-
eral molecular markers have been characterized with respect to
these clinical expectations. We review candidate molecules
that have been investigated so far for anaplastic gliomas
(WHO grade III) and for glioblastomas (WHO grade IV).
O6 Methylguanine DNA methyltransferase (MGMT)
The DNA repair protein MGMT rescues the DNA damage
induced by alkylating chemotherapy (eg, lomustine or temo-
zolomide) by removing the alkyl group from the O6 position of
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guanine. During this repair process MGMT is irreversibly
degraded and needs to be resynthesized de novo. As a conse-
quence, theMGMT protein reservoir is potentially exhaustible.
Early studies have examined the prognostic value of MGMT
protein expression by immunohistochemistry and failed to
consistently demonstrate a correlation with outcome. Of note,
interobserver variation was also considerable [3]. The gold
standard of protein determination in freshly isolated tumor
tissue is of limited practical use, as it requires immediate
processing of fresh tumor samples after surgery. Most recent
studies analyzed the methylation of theMGMT gene promoter
rather than protein levels or enzyme activity in glioma cells.
Methylation of the gene promoter leads to silencing of tran-
scription and thus lack of translation and absence of synthesis
of functional protein. MGMT promoter methylation data con-
sistently correlated better with clinical outcome than immuno-
histochemical evidence of MGMT protein in glioma tissue [3].
This might be due to the differential accuracy of the methods
and to the fact that immunohistochemical MGMT detection
precludes the precise distinction of MGMT-positive glioma
cells from host-derived glioma-infiltrating non-neoplastic cells
(eg, microglia) [4, 5]. In contrast, determination of MGMT
promoter methylation using methylation-specific assays essen-
tially detects an acquired abnormality thought to be derived
exclusively from tumor cells.
An association of MGMT gene promoter methylation and
the benefit from alkylating chemotherapy was investigated
within the randomized pivotal European Organisation of
Research and Treatment of Cancer (EORTC)—National Can-
cer Institute of Canada Clinical Trials Group (NCIC) phase III
trial (EORTC 26981/22981-NCIC CE.3), which demonstrated
improved survival when temozolomide was added to radiother-
apy in newly diagnosed glioblastomas [6]. Methylation of the
MGMT promoter in glioblastomas correlated with patients’
benefit from adding temozolomide to radiotherapy [7] while
there was little effect on progression-free survival in patients
receiving radiotherapy alone. These data suggested thatMGMT
promoter methylation is rather a predictive marker of benefit
from temozolomide in glioblastomas.
In an attempt to overcome MGMT-mediated resistance
by dose-dense (21/28 days) temozolomide administration,
the Radiation Therapy Oncology Group (RTOG)—EORTC
Intergroup trial 0525 compared standard dosing regimen of
temozolomide (5/28 days) dosage with dose-dense temozo-
lomide after completion of radiotherapy and concomitant
temozolomide. No difference in outcome (ie, progression-
free or overall survival) was seen with no hint for a benefit
from dose-intensified temozolomide in any subgroup of
patients. Nevertheless, patients with MGMT promoter-
methylated glioblastomas had a significantly superior over-
all survival (median, 23.2 months) compared to patients
with unmethylated glioblastomas (median, 16 months) [8].
Recently, a study of the German Glioma Network analyzed
MGMT promoter methylation in 233 elderly patients older
than 70 years of age with glioblastomas (median age,
74 years) and correlated the MGMT status with patients’
clinical outcome. Progression-free survival of patients with
MGMT-methylated glioblastomas was longer when treated
with radiotherapy plus temozolomide or temozolomide
alone compared to patients receiving radiotherapy alone.
On the other hand, patients with MGMT-unmethylated glio-
blastomas did not gain any significant survival benefit from
temozolomide [9•]. Confirmation of these findings in pro-
spective trials is needed to make individual treatment deci-
sions based on the MGMT promoter methylation status.
Specifically, it remains to be clarified whether elderly
patients with MGMT-methylated glioblastomas should be
treated with alkylating agent chemotherapy and deferred
radiotherapy, while radiotherapy alone should be the treat-
ment of choice for elderly patients with an MGMT-unme-
thylated promoter. Interestingly, treatment with alkylating
agent therapy does not select for loss of MGMT methylation
in glioblastoma, as has been determined by the German
Glioma Network investigating MGMT promoter methyla-
tion in paired primary and recurrent glioblastomas [10•].
This finding is in line with the discovery of a mutator
phenotype in MGMT-methylated glioblastoma after alkylat-
ing agent therapy allowing for selection of treatment-
induced genetic alterations resulting in therapy resistance
such as mutations in the MSH6 gene, which is part of the
mismatch repair pathway, that might also blunt the treatment
efficacy of alkylating agents [11, 12•].
In the NOA-04 randomized trial, the impact of sequential
treatments with chemotherapy or radiotherapy in patients
with anaplastic gliomas was explored. Patients received
radiotherapy or alkylating chemotherapy (ie, temozolomide
or procarbazine, lomustine, and vincristine [PCV]) at initial
diagnosis, and after progression chemotherapy or irradia-
tion, respectively. There was no difference in overall out-
come and the sequence of treatments did not matter. Overall,
patients with a methylated MGMT gene promoter had a
better outcome.
Interestingly, time to first treatment progression was com-
parable for both treatment arms even in the subgroup of
patients with a methylated MGMT promoter, thus suggesting
that in anaplastic gliomas the MGMT status is of prognostic
value without prediction of benefit from alkylating agent
chemotherapy [13]. This was confirmed in an EORTC trial
demonstrating that MGMT promoter methylation was prog-
nostic but not predictive for outcome to PCV in anaplastic
oligodendrogliomas [14]. Thus, the predictive role of MGMT
for benefit of temozolomide chemotherapy observed in glio-
blastomas cannot be extrapolated to other grades of glioma.
Of note, methylation of the MGMT promoter is indicative of
other associated alterations in anaplastic glioma predicting a
superior clinical outcome notably co-deletion of 1p/19q and
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mutations in the isocitrate dehydrogenase (IDH)1 gene. This
finding has been further clarified by the discovery of a glioma
CpG island methylator phenotype (G-CIMP) present in over
45% of anaplastic glioma that was prognostic for outcome,
and was highly correlated with IDH1 mutations, 1p/19q co-
deletions, and MGMT methylation [15]. Originally, G-CIMP
was discovered in glioblastoma when screening 272 glioblas-
toma samples from The Cancer Genome Atlas (TCGA) pro-
ject for genome-wide DNA methylation by Noushmehr et al.
[16]. In glioblastoma, G-CIMP is infrequent, present in less
than 10% of the cases, and strongly associated with mutations
of IDH1 and with superior clinical outcome. Subsequent
studies suggest that IDH1 mutations and, therefore, also
G-CIMP, identify secondary glioblastoma that progress from
lower-grade lesions. These findings have elucidated the evo-
lution of gliomas, pathogenetically clearly separating primary
glioblastoma from secondary glioblastoma and lower-grade
gliomas. Thus, in future prospective randomized clinical trials,
stratifications for the methylator phenotype and/or IDH muta-
tions should be considered. Further, studying cancer-relevant
pathways affected by the methylator phenotype may reveal
novel promising drug targets.
Currently ongoing clinical trials for glioblastomas patients
use the MGMT gene promoter methylation status as selection
criterion for study inclusion (Fig. 1) or stratification factor.
Studies selecting MGMT-methylated patients only, expect a
synergistic effect of their novel agent with temozolomide
treatment. In contrast, selecting MGMT-unmethylated glio-
blastoma patients, allows omission of temozolomide. This
allows testing of new drugs with a different mode of action
and provides the opportunity to develop new treatment
strategies to improve the outcome in these patients who gain
less benefit from the current standard of care.
Combined Deletions of Chromosomes 1p and 19q
Investigations using microsatellite markers identified a fre-
quent combined loss of heterozygosity (LOH) on the short
arm of chromosome 1 (1p) and the long arm of chromosome
19 (19q) in malignant gliomas [17]. This combined loss is
now commonly referred to as 1p/19q co-deletions and usually
affects the whole chromosomal arms that seems to be medi-
ated by a t(1;19)(q10;p10). Interestingly, this combination of
LOH is almost never found in any non-glial malignancy.
Moreover, 1p/19q co-deletions are commonly associated with
oligodendroglial differentiation. Histological evidence of an
oligodendroglioma or at least an oligodendroglial component
in a mixed glioma is virtually always coupled with an IDH1/2
mutation [18]. Patients with oligodendroglioma that harbor
1p/19q deletions have superior outcome after radiotherapy
and chemotherapy [19]. In glioblastomas, on the other hand,
1p/19q deletions are rare and do not predict prognosis of
patients [20].
The identification of frequent 1p/19q co-deletions in
malignant gliomas and the clinical relevance of this finding
for predicting response to therapy of oligodendroglioma
patients indicated the presence of tumor suppressor genes
or other genes with important roles for radiotherapy- or
chemotherapy-induced cell death in these chromosomal
regions. Recently, candidate genes have been identified by
exome sequencing (sequencing of all coding exons).
Fig. 1 Enrollment into clinical glioblastomas trials based on MGMT
methylation status. CENTRIC, addition of cilengitide to standard therapy
compared with standard treatment in newly diagnosed glioblastomas
(recruitment completed). CeTeG, addition of lomustine to standard ther-
apy compared with standard treatment in newly diagnosed glioblastomas
(recruitment ongoing). EORTC 26082/22081, temsirolimus plus radio-
therapy compared with standard treatment in newly diagnosed glioblas-
tomas (recruitment ongoing). CORE, standard therapy with cilengitide
either twice weekly or five times per week versus standard therapy in
newly diagnosed glioblastomas (recruitment ongoing), GLARIUS, bev-
acizumab and irinotecan versus standard therapy in newly diagnosed
glioblastomas (recruitment ongoing), S039, enzastaurin before and con-
comitant with radiotherapy followed by enzastaurin maintenance in new-
ly diagnosed glioblastomas (recruitment completed). The ClinicalTrials.
gov identifier numbers are indicated in the figure
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Mutations have been identified in CIC, a homolog of the
Drosophila gene capicua, on chromosome 19q, and the
FUBP1 gene (far upstream element binding protein 1), on
chromosome 1p [21]. The functional roles of CIC and
FUBP1 in the pathogenesis of these tumors are currently
under investigation.
Currently ongoing clinical trials include patients with
anaplastic gliomas only after determination of 1p/19q status
(eg, CATNON trial [NCT00626990] or the CO-DEL trial
[NCT00887146]), further emphasizing the impact of this
genetic marker for clinical neuro-oncology.
Isocitrate Dehydrogenase
Somatic mutations of the IDH1 gene were identified by a
whole-genome mutational analysis in glioma tissue sam-
ples [22]. The mutations occur at codon 132 of the IDH1
gene, and less frequently at corresponding codons of
IDH2 [22, 23], and were found in about 60% to 80%
of astrocytomas and oligodendrogliomas of grades II and
III but in less than 10% of glioblastomas. In glioblasto-
mas, the presence of IDH1 mutations likely identifies
secondary glioblastomas that originate from a prior
lower-grade glioma [24]. This biomarker reliably identi-
fies patients with a more favorable prognosis independent
of treatment [13, 25, 26].
The neomorphic IDHmutants give rise to the production of
D-2-hydroxyglutarate (2-HG) that accumulates to high levels
in glioma [27]. The oncometabolite 2-HG is a competitive
inhibitor ofα-ketoglutarate-dependent dioxygenases, reducing
the activities of the families of histone demethylases and TET
5-methylcytosine hydroxylases, including the tet oncogene
family member TET2, resulting in widespread epigenetic
changes. Interestingly, in acute myeloid leukemia (AML),
IDH1 and IDH2 mutations are also associated with a methyl-
ator phenotype, and were shown to be mutually exclusive with
loss-of-function mutations in the TET2 gene. These observa-
tions suggests a functional link between IDH1/2mutations, the
production of 2-HG, and the development of a methylator
phenotype in glioma and AML (ie, metabolism meets epige-
netics) [28••, 29]. The concentrations of the oncometabolite
2-HG in the blood can be used to monitor disease activity in
patients with AML. However, 2-HG levels in the serum of
glioma patients are not suitable as surrogate markers. The
levels do not correlate with the presence of IDH1 or IDH2
mutations in the glioma tissue nor with tumor size [30]. This
might be due to the fact that in contrast to AML, the actual
tumor site is not the blood but the brain. This might account for
too low concentrations in peripheral blood of glioma patients.
Of note, concentrations of 2-HG in the cerebrospinal fluid have
not yet been analyzed for 2-HG levels. Currently, efforts aim at
detecting 2-HG by magnetic resonance spectroscopy that
would provide a noninvasive diagnostic tool to identify
IDH1/2 mutant gliomas [31].
Recently, an antibody has been developed recognizing the
mutant IDH1-R132H protein [32], which accounts for over
90% of all mutations in glioma. The development of this
antibody has facilitated the widespread use of this marker, the
rapid acquisition of data, and correlation with clinical outcome.
The survival of patients with IDH1-mutant astrocytomas or
oligodendrogliomas of grades II-III and including glioblastoma
is longer than that of their IDH wild-type counterparts. Impor-
tantly, overall survival of patients with IDH1-mutated glioblas-
tomas (WHO grade IV) is better than for patients with IDH1
wild-type anaplastic astrocytomas (WHO grade III) [33], con-
firming the potential of molecular markers to improve outcome
prediction and clinical utility of the WHO classification.
IDH status reliably identifies patients with a more favorable
prognosis but does not predict treatment-specific responses of
glioma patients [13, 34, 35••, 36–38], at least according to
currently available data, and has not yet led to novel treatment
strategies for malignant gliomas. In the future, clinical trials
with IDH1 status as enrollment criteria might help to further
define the impact of this molecular feature on clinical neuro-
oncology. Given the fact that the antibody is already available
for neuropathological histology diagnostics, it might be even
easier to call for an upfront IDH1 status before enrollment into
clinical trials than for an MGMT status. For example, a pos-
sible strategy might be to exclude glioblastoma patients with
IDH mutations from future glioblastoma trials.
Epidermal Growth Factor Receptor
Amplifications of epidermal growth factor receptor (EGFR)
are frequent in primary glioblastomas [11, 20]; overexpres-
sion of EGFR has been associated with shorter survival in
glioblastoma. Several compounds targeting EGFR are avail-
able for clinical use, and have also been evaluated in malig-
nant glioma. Neither of these demonstrated satisfying anti-
glioma activity, although bioavailability and activity to de-
phosphorylate the EGFR in the tumor tissue could be shown
for gefitinib in a phase II trial [39•]. The prospective ran-
domized phase II EORTC 26034 trial on erlotinib in unse-
lected recurrent glioblastoma did not demonstrate any
evidence for antitumor activity [40]. A recent randomized
trial investigated afatinib, a high-affinity irreversible EGFR
tyrosine kinase inhibitor, versus dose-dense temozolomide
(21/28 days) alone or the combinations of both. Again, no
evidence of antitumor activity of EGFR inhibition could be
shown [41]. Currently, the EGFR status does not impact
clinical practice in neuro-oncology in any direction. The
EGFRvIII mutation, a specific subtype of EGFR mutations,
Curr Neurol Neurosci Rep (2012) 12:302–307 305
might be used in the future for selecting patients for clinical
trial enrollment. This specific mutation encodes for a con-
stitutively active receptor and might be a useful target for
immunotherapy [42].
Circulating Biomarkers
The investigation of circulating molecules or cells in
peripheral blood and urine in patients with malignant
gliomas has regained attention by the emergence of sev-
eral antiangiogenic compounds. None of these parameters
have entered routine clinical practice decision making
yet. In a phase II trial investigating cediranib in patients
with recurrent glioblastomas, plasma and urine were col-
lected at baseline and at several defined time points after
start of study medication. Increased levels of metallopro-
teinase 2 in plasma and increased levels of metallopro-
teinase 9 in urine were correlated with poor progression-
free survival, whereas increased plasma levels of placen-
tal growth factor and basic fibroblast factor were corre-
lated with longer overall survival. Increased plasma
levels of stromal-derived factor 1, soluble vascular
growth factor receptor 1, and soluble Tie 2 were corre-
lated with radiographic tumor progression [2]. The value
of circulating biomarkers still needs to be further defined
in future clinical trials.
Conclusions
Biomarkers are an emerging field also for neuro-
oncology. Considerable progress has been made in iden-
tifying, characterizing, and applying molecular markers.
These efforts will certainly refine the current histomor-
phologically based WHO classification in the future. In
the present daily clinical decision making for the treat-
ment of patients with malignant gliomas, however, mo-
lecular markers are barely used. The lack of better
strategies for MGMT-unmethylated patients and limita-
tions of accurate determination of the MGMT status
limit its applicability in daily practice outside clinical
trials. Deletion of 1p/19q allows identification of a
prognostically more favorable subgroup; the ongoing
randomized clinical trials will determine whether this
allows one to adapt the treatment strategy individually.
As outlined above, the identification of the IDH1 status
demonstrates that this molecular aberration can be used
to amend and refine the existing WHO classification.
The recognition of IDH-mutated secondary glioma as a
distinct pathogenetic entity will therefore very likely
influence the next revision of the WHO classification.
On the other hand, currently ongoing powerful high-
throughput analyses will most probably identify novel
so-far unknown candidate molecules that could poten-
tially serve as biomarkers for malignant gliomas. Yet,
the identification of new markers will hopefully be
paralleled by the identification of new drugs for the
treatment of patients with malignant gliomas.
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